Parallel import

The original manufacturer produces pharmaceuticals in various European countries. The pharmaceuticals are then sold in several European markets. In each of the European countries differing laws and healthcare supply structures are relevant for pricing. This results in different selling prices.

HAEMATO is using these price differences by buying the pharmaceuticals from different wholesalers around Europe at a lower price than they are available in Germany. The pharmaceuticals are then imported into Germany and licensed seperately before they are sold to national wholesalers and pharmacies. The outer and inner packaging of every pharmaceutical must be changed according to the requirements of the German Federal Institute for Drugs and Medical Devices (BfArM) and the European Medicines Agency (EMA).  


Die HAEMATO AG ist ein börsennotiertes pharmazeutisches Unternehmen mit Fo-kus auf die Wachstumsmärkte patentfreier und patentgeschützter Arzneimittel...


IFRS-Ergebnis Q1 2017, Umsatz 67,9 Mio. Euro (Vorjahresperiode: 67,9 Mio. Euro), EBIT 2,8 Mio. Euro (Vorjahresperiode: 3,5 Mio. Euro)...


2016: Vorläufiges IFRS-Ergebnis, Umsatzwachstum 20% auf 275,6 Mio. Euro, EBIT-Wachstum (operatives Ergebnis) 63% auf 13,4 Mio. Euro;...

Order service - Telephone: +49 30 677 98 67 60
Aktuelle News